Effectiveness of Fimasartan and Rosuvastatin Combination Treatment in Hypertensive Patients With Dyslipidemia

The goal of this study was to evaluate the concurrent control rate of hypertension and dyslipidemia by fimasartan and rosuvastatin in patients who were concomitantly prescribed both drugs. : This single-center, cross-sectional study was conducted in 536 patients with hypertension and dyslipidemia wh...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical therapeutics 2020-06, Vol.42 (6), p.1058-1066.e3
Hauptverfasser:	Lee, Seung-Jun, Oh, Jaewon, Hong, Sung-Jin, Cho, In-Jeong, Kim, Su Rae, Uhm, Jae-Sun, Shim, Chi Young, Chang, Hyuk-Jae, Ahn, Chul-Min, Kim, Jung-Sun, Kim, Byeong-Keuk, Park, Sungha, Lee, Sang-Hak, Hong, Geu Ru, Ko, Young-Guk, Choi, Donghoon
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged angiotensin receptor blocker Anticholesteremic Agents - administration & dosage Antihypertensive Agents - administration & dosage Antihypertensives Arteriosclerosis Atherosclerosis Biphenyl Compounds - administration & dosage Blood pressure Blood Pressure - drug effects Cardiovascular disease Cardiovascular diseases Cholesterol Cholesterol, LDL - blood Clinical medicine Coronary vessels Cross-Sectional Studies Drug dosages Drug Therapy, Combination Dyslipidemia Dyslipidemias - blood Dyslipidemias - drug therapy Dyslipidemias - physiopathology Enrollments Evaluation Fatalities Female fimasartan Health risks Health services High density lipoprotein Humans Hypertension Hypertension - blood Hypertension - drug therapy Hypertension - physiopathology Lipids Low density lipoprotein Male Metabolic disorders Middle Aged Patients Physicians Pyrimidines - administration & dosage Risk Risk groups rosuvastatin Rosuvastatin Calcium - administration & dosage Statins Synergistic effect Tetrazoles - administration & dosage Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The goal of this study was to evaluate the concurrent control rate of hypertension and dyslipidemia by fimasartan and rosuvastatin in patients who were concomitantly prescribed both drugs. : This single-center, cross-sectional study was conducted in 536 patients with hypertension and dyslipidemia who were taking fimasartan and rosuvastatin together for at least 12 weeks. Patients were enrolled from October 2016 to March 2018 at a tertiary hospital in the Republic of Korea. The primary end point was the concurrent control rate of blood pressure (
ISSN:	0149-2918 1879-114X
DOI:	10.1016/j.clinthera.2020.03.019